TITLE

INIMEX RAISES US $22 MIL AGAINST ANTIBIOTIC RESISTANCE

PUB. DATE
July 2008
SOURCE
Biotech Financial Reports;Jul2008, Vol. 15 Issue 7, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the $22 million venture funds received by Inimex Pharmaceuticals, Inc. The venture funds allow Inimex Pharmaceuticals, Inc. to conduct clinical trials of an Innate defense Regulator (IDR) drug in patients. They are donated by several investors including Morningside Venture Investments Ltd., Roche Venture Fund, Astellas Venture Management LLC, and Advantage Life Science Fund II.
ACCESSION #
32925995

 

Related Articles

  • INIMEX BEGINS CLINICAL STUDY OF INNATE DEFENSE REGULATOR.  // Worldwide Biotech;Jun2009, Vol. 21 Issue 6, p6 

    The article reports that Inimex Pharmaceuticals administered Innate Defense Regulator (IDR) IMX942 on April 27, 2009 to healthy volunteers enrolled in the phase 1 study with Health Canada. IMX942 is treatment for the reduction of bacterial infections and decrease of inflammation. Said trial aims...

  • Inimex Nets $22M in Series B to Advance Innate Defense Drugs. Turner, Tiffany // BioWorld Today;6/3/2008, Vol. 19 Issue 107, p1 

    The article talks about the successful Series B financing held by Inimex Pharmaceuticals Inc., that it expects to bring it closer to conducting clinical trials of its Innate Defense Regulator drugs. The company raised $22 million to grow its portfolio, which includes a number of potential...

  • Oxyrane Brings in $26.5M To Fund Pompe's Drug R&D. Moran, Nuala // BioWorld Today;11/18/2011, Vol. 22 Issue 225, p1 

    The article reports on the 26.5 million U.S. dollars raised by Oxyrane Ltd. in a fourth private round. The funds will be used to move the company's first enzyme replacement therapy into clinical development for the treatment of Pompe's disease. The investors involved in the fundraising were...

  • Traversa Gets $5M Series B to Move Programs Toward Clinic.  // BioWorld Today;4/3/2009, Vol. 20 Issue 63, p2 

    The article reports that Traversa Therapeutics has raised $5 million in a Series B financing that will help advance its RNA interference (RNAi) oncology programs into clinical trials. The deal was led by Morningside Venture Investments Ltd., joined by Mesa Verde Venture Partners and existing...

  • Inimex Nets $22M to Advance Innate Defense.  // Bioworld Week;6/9/2008, Vol. 16 Issue 23, p2 

    The article reports that Inimex Pharmaceuticals Inc. of Vancouver, British Columbia has raised $22 million to advance its portfolio which includes products for combating antibiotic resistance and inflammation. The company is developing a series of non-antibiotic drugs designed to trigger the...

  • CLINIC ROUNDUP.  // BioWorld Today;4/29/2009, Vol. 20 Issue 81, p3 

    This section offers news briefs concerning the biotechnology industry. A Phase I trial of AERAS-402/Crucell Ad35 tuberculosis vaccine has been started by Crucell NV and the Aeras Global TB Vaccine Foundation. Inimex Pharmaceuticals Inc. has commenced its Phase I study of IMX942, an innate...

  • The Cost of Clinical Trials. Fee, Robert // Drug Discovery & Development;Mar2007, Vol. 10 Issue 3, p30 

    The article reports on the predicted growth of the national spending on clinical trials in the U.S. According to a report, research institutes expects that the spending would rise to $25.6 billion in 2006 and $32.1 billion in 2011, with a growing average rate of 4.6% per year. On the other hand,...

  • Serica closes on $6M funding; $500K invested in Apeliotus.  // Medical Device Daily;11/20/2008, Vol. 12 Issue 227, p4 

    The article reports that Serica Technologies has closed on $6 million of additional funding with support from existing investors Morningside Technology Ventures, Prism VentureWorks and Ivy Capital Partners in 2008. It was mentioned that Serica is a growth-stage device company developing...

  • Vivus' Late-Stage Pipeline Gets $65M Boost.  // Bioworld Week;8/11/2008, Vol. 16 Issue 32, p3 

    The article reports that Vivus Inc. agreed to sell 8.4 million shares of common stock to new and existing investors at a price $7.77 each. According to the company the net proceeds are expected to total about $63.4 million and will add to the $155 million Vivus had in the bank. As of June 30,...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics